These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4220831)

  • 1. Interrelationship of human plasma kallikrein and plasmin in inflammation.
    Webster ME; Innerfield I
    Enzymol Biol Clin (Basel); 1965; 5(3):129-48. PubMed ID: 4220831
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of a serine proteinase inhibitor from Leucaena leucocephala on plasma kallikrein and plasmin.
    Souza-Pinto JC; Oliva ML; Sampaio CA; Damas J; Auerswald EA; Limãos E; Fritz H; Sampaio MU
    Immunopharmacology; 1996 Jun; 33(1-3):330-2. PubMed ID: 8856177
    [No Abstract]   [Full Text] [Related]  

  • 3. Actions of urinary kallikrein, plasmin, and other kininogenases on bovine plasma high-molecular-weight kininogen.
    Han YN; Kato H; Iwanaga S; Komiya M
    J Biochem; 1978 Jan; 83(1):223-35. PubMed ID: 146707
    [No Abstract]   [Full Text] [Related]  

  • 4. Generation of kinin by plasma kallikrein and plasmin and the effect of alpha1-antitrypsin and antithrombin III on the kinongenases.
    Habal FM; Burrowes CE; Movat HZ
    Adv Exp Med Biol; 1976; 70(00):23-36. PubMed ID: 132848
    [No Abstract]   [Full Text] [Related]  

  • 5. Proceedings: Activation of the inactive precursor of collagenase by kallikrein and plasmin.
    Eeckhout Y; Vaes G
    Arch Int Physiol Biochim; 1974 Oct; 82(4):786. PubMed ID: 4141456
    [No Abstract]   [Full Text] [Related]  

  • 6. Human inter-alpha-trypsin inhibitor. Limited proteolysis by trypsin, plasmin, kallikrein and granulocytic elastase and inhibitory properties of the cleavage products.
    Dietl T; Dobrinski W; Hochstrasser K
    Hoppe Seylers Z Physiol Chem; 1979 Sep; 360(9):1313-8. PubMed ID: 92450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders.
    Sakamaki H; Ogura N; Kujiraoka H; Akiba M; Abiko Y; Nagura H
    Int J Oral Maxillofac Surg; 2001 Aug; 30(4):323-8. PubMed ID: 11518356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent studies of the synthetic selective inhibitors; with special reference to non-plasmin fibrinolytic enzyme, plasmin and plasma-kallikrein.
    Okamoto S; Okamoto U; Hijikata-Okunomiya A; Wanaka K; Okada Y
    Thromb Res Suppl; 1988; 8():131-41. PubMed ID: 2974647
    [No Abstract]   [Full Text] [Related]  

  • 9. Hydrolysis of plasma kallikrein by trypsin and plasmin and the formation of active fragments.
    Sampaio CA; Vidmar S; Hamaguchi A; Sampaio MU
    Adv Exp Med Biol; 1986; 198 Pt B():105-11. PubMed ID: 2949543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of tripeptide chloromethyl ketones and examination of their inhibitory effects on plasmin and plasma kallikrein.
    Tsuda Y; Teno N; Okada Y; Wanaka K; Bohgaki M; Hijikata-Okunomiya A; Okamoto U; Naito T; Okamoto S
    Chem Pharm Bull (Tokyo); 1989 Nov; 37(11):3108-11. PubMed ID: 2534361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of human high molecular weight kininogen digestion by plasma kallikrein and by plasmin. A revised method of purification of high molecular weight kininogen.
    Kleniewski J; Donaldson VH
    J Lab Clin Med; 1987 Apr; 109(4):469-79. PubMed ID: 2950194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methionyl-lysyl-bradykinin release from plasma kininogen by plasmin.
    Henriques OB; Gapanhuk E; Kauritcheva N; Budnitskaya P
    Biochem Pharmacol; 1969 Jul; 18(7):1789-90. PubMed ID: 4241079
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma kallikrein and plasmin as activators of prorenin: links between the renin-angiotensin system and other proteolytic systems in plasma.
    Schalekamp MA; Derkx FH
    Clin Sci (Lond); 1981 Jul; 61(1):15-21. PubMed ID: 6454526
    [No Abstract]   [Full Text] [Related]  

  • 14. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors.
    Schapira M; Scott CF; James A; Silver LD; Kueppers F; James HL; Colman RW
    Biochemistry; 1982 Feb; 21(3):567-72. PubMed ID: 6175341
    [No Abstract]   [Full Text] [Related]  

  • 15. [The kinin and plasmin systems of the blood serum and cerebro- spinal fluid in patients with multiple sclerosis and schizophrenia].
    Vilkov GA; Martirosian VV; Trapezontseva RA; Kozlova LS; Ellanskiĭ IuIu
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(7):23-7. PubMed ID: 2477972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of plasma prekallikrein and inactive renin by puff adder venom.
    Morris BJ; Lawrence CH; Catanzaro DF
    Clin Exp Pharmacol Physiol; 1980; 7(5):563-7. PubMed ID: 6450010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New synthetic substrate for kallikrein and its application.
    Fujii S; Hitomi Y; Kimura K; Ishii M; Kurumi M; Aoyama T
    Adv Exp Med Biol; 1986; 198 Pt A():299-308. PubMed ID: 2949541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein.
    Sealey JE; Atlas SA; Laragh JH; Silverberg M; Kaplan AP
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5914-8. PubMed ID: 42905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on plasma kallikrein and its relationship to plasmin.
    WEBSTER ME; PIERCE JV
    J Pharmacol Exp Ther; 1960 Dec; 130():484-91. PubMed ID: 13783664
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulation of 92-kDa gelatinase B activity in the extracellular matrix by tissue kallikrein.
    Menashi S; Fridman R; Desrivieres S; Lu H; Legrand Y; Soria C
    Ann N Y Acad Sci; 1994 Sep; 732():466-8. PubMed ID: 7978840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.